Literature DB >> 16359469

Genetics of drug resistance.

Sanjay M Sisodiya1.   

Abstract

Drug resistance in epilepsy affects about a third of patients and is an important clinical problem, associated with increased morbidity and mortality. It is important to consider carefully the definition of drug resistance. Recent interest in the field has focused on the potential molecular mechanisms underlying drug resistance. Environmental and seizure-related acquired causes are likely to contribute to the multifaceted basis of resistance in most cases. Genetic causes have attracted particular attention, partly because they may allow prediction of drug resistance and, potentially, rational treatment strategies. Gene mutations, however, are unlikely to cause many cases of drug resistance. However, common variation in genes probably will turn out to generate an important contribution to drug resistance phenomena. Associations between common variations in a number of genes and clinical drug resistance have now been published. However, to date, none of these associations has been unequivocally replicated by others to the extent that the original association has been accepted. Some of these associations are considered. Despite this apparently uninspiring record, the genetics of drug resistance are likely to prove productive in the near future, but their pursuit will require painstaking studies and multicenter collaboration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359469     DOI: 10.1111/j.1528-1167.2005.00356.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

1.  Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.

Authors:  Ram Lakhan; Ritu Kumari; Kavita Singh; Jayanti Kalita; Usha Kant Misra; Balraj Mittal
Journal:  Indian J Med Res       Date:  2011-09       Impact factor: 2.375

2.  Genetic polymorphism of drug refractory epilepsy.

Authors:  R Kesavan; Ritushree Kukreti; C Adithan
Journal:  Indian J Med Res       Date:  2011-09       Impact factor: 2.375

3.  Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.

Authors:  Xue Yang; Yuanliang Yan; Shu Fang; Shuangshuang Zeng; Hongying Ma; Long Qian; Xi Chen; Jie Wei; Zhicheng Gong; Zhijie Xu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 4.  Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?

Authors:  Liliana Czornyj; Jerónimo Auzmendi; Alberto Lazarowski
Journal:  Epilepsia Open       Date:  2021-10-29

5.  Antiepileptic drug monotherapy: the initial approach in epilepsy management.

Authors:  Erik K St Louis; William E Rosenfeld; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

Review 6.  Epilepsy research: a window onto function to and dysfunction of the human brain.

Authors:  Heinz Beck; Christian E Elger
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

7.  Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.

Authors:  Armond Daci; Giangiacomo Beretta; Driton Vllasaliu; Aida Shala; Valbona Govori; Giuseppe Danilo Norata; Shaip Krasniqi
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.